$174.38
+111.42 (+176.97%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MRNA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
94 interventional · 19 observational · 33 with posted results
Held by 17 tracked-famous managers (BAILLIE GIFFORD & CO, TWO SIGMA INVESTMENTS, LP, Qube Research & Technologies Ltd, AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, +12 more) · FINRA short interest 10.2 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705NCT05295433Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Drug-Related TEAEs, Unrelated TEAEs, Adverse Events of Special Interests (AESIs), Serious Adverse Events (SAEs) and TEAEs Leading to DiscontinuationOpen-label · Treatment | Phase 1/2 | Recruiting | Drug: mRNA-3705 | Methylmalonic Acidemia | 56 | 2034-04-02 | in 2,782 d | 2025-12-23 |
| An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)NCT03897881Recurrence-Free Survival (RFS), Assessed Using Radiological ImagingRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: mRNA-4157 · Biological: Pembrolizumab | Melanoma | 267 | 2032-11-30 | in 2,294 d | 2025-12-03 |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsNCT05533697Arms 1a and 1b: Maximum Tolerated Dose (MTD) or Recommended Dose for Expansion (RDE) of mRNA-4359Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab | Advanced Solid Tumors | 361 | 2032-02-18 | in 2,008 d | 2026-07-14 |
| A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaNCT07116616Number of Participants with Dose-limiting ToxicityOpen-label · Treatment | Phase 1/2 | Recruiting | Drug: mRNA-2808 | Relapsed or Refractory Multiple Myeloma | 166 | 2030-06-17 | in 1,397 d | 2026-07-24 |
| A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 StudyNCT05130437Number of Participants with Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to DiscontinuationOpen-label · Treatment | Phase 1/2 | Recruiting | Biological: mRNA-3927 | Propionic Acidemia | 50 | 2029-12-04 | in 1,202 d | 2026-03-23 |
| A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsNCT05743881Main Study: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Triple-masked · Treatment | Phase 1 | Active, not recruiting | Biological: mRNA-1345, mRNA-1365, Placebo · Drug: Nimenrix | Respiratory Syncytial Virus, Human Metapneumovirus | 186 | 2029-08-31 | in 1,107 d | 2026-06-26 |
| Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGENCT06333704observationalNumber of Participants With AEs | — | Active, not recruiting | Biological: SPIKEVAX Bivalent BA.1, SPIKEVAX Bivalent BA.4/5, SPIKEVAX XBB.1.5, SPIKEVAX JN.1 | SARS-CoV-2 | 4,207 | 2029-03-29 | in 952 d | 2026-04-16 |
| A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsNCT06735248Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Biological: mRNA-1195, Placebo | Multiple Sclerosis | 180 | 2029-01-08 | in 872 d | 2026-06-15 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)NCT07561294Both Phases: Number of Participants with Solicited Local and Systemic Adverse ReactionsRandomized · Single-masked · Prevention | Phase 2 | Active, not recruiting | Biological: mRNA-1982, Placebo | Lyme Disease | 366 | 2028-11-09 | in 812 d | 2026-08-03 |
| Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsNCT03313778Number of Participants with Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: mRNA-4157, Pembrolizumab, SoC Treatment | Solid Tumors | 161 | 2027-11-21 | in 458 d | 2026-03-04 |
| A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)NCT06189053observationalNumber of Participants with Major Adverse Clinical Outcomes | — | Active, not recruiting | — | Myocarditis | 1,500 | 2027-10-31 | in 437 d | 2025-08-01 |
| A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult ParticipantsNCT07737717Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 1 | Recruiting | Biological: mRNA-1469, Placebo | Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | 84 | 2027-09-30 | in 406 d | 2026-08-11 |
| Open-Label Study of mRNA-3927 in Participants With Propionic AcidemiaNCT04159103Part 1: Number of Participants with Treatment-emergent Adverse Event (TEAE), Serious Adverse Events (SAE) and TEAEs Leading to DiscontinuationOpen-label · Treatment | Phase 1/2 | Recruiting | Biological: mRNA-3927 | Propionic Acidemia | 77 | 2027-08-31 | in 376 d | 2026-01-22 |
| A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsNCT06880549Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Biological: mRNA-4106, Pembrolizumab, mRNA-4200 | Advanced Solid Tumors | 42 | 2027-08-03 | in 348 d | 2026-08-10 |
| A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsNCT07764237Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 1 | Recruiting | Biological: mRNA-1365 (Profile 2), mRNA-1345 (Profile 1), mRNA-1345 (Profile 3) | Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV) | 375 | 2027-07-20 | in 334 d | 2026-08-19 |
| A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)NCT07266558VE of mRNA-1273 (Variant Formulation) to Prevent the First Event of Symptomatic COVID-19 after Study InjectionRandomized · Triple-masked · Prevention | Phase 4 | Active, not recruiting | Biological: mRNA-1273, mRNA-1283, Placebo | SARS-CoV-2 | 30,000 | 2027-06-16 | in 300 d | 2026-04-28 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of AgeNCT07478952Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Open-label · Prevention | Phase 1 | Recruiting | Biological: mRNA-1189 | Epstein-Barr Virus | 120 | 2027-05-15 | in 268 d | 2026-03-24 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.NCT05683457Time to the First Occurrence of an CS-CMVi Event as Measured by initiation of anti-CMV Antiviral TherapyRandomized · Triple-masked · Prevention | Phase 2 | Active, not recruiting | Biological: mRNA-1647, Placebo | Cytomegalovirus Infection | 84 | 2027-03-06 | in 198 d | 2026-08-10 |
| A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisNCT06592794Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Triple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: mRNA-1403, Placebo | Acute Gastroenteritis, Norovirus Acute Gastroenteritis | 37,864 | 2027-02-15 | in 179 d | 2026-05-13 |
| A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsNCT07496450Percentage of Participants With Hemagglutination Inhibition (HAI) Titer ≥ 1:40 at Day 43Randomized · Triple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: mRNA-1018-H5, Placebo | Influenza | 4,050 | 2027-01-28 | in 161 d | 2026-08-11 |
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsNCT06585241mRNA-1273.167, mRNA-1273.712, mRNA-1273.251, and mRNA-1273.261: Geometric Mean Value of Neutralizing Antibody Against COVID-19 VariantsOpen-label · Prevention | Phase 4 | Recruiting | Biological: mRNA-1273 Variant-containing Formulation | SARS-CoV-2 | 1,144 | 2026-12-31 | in 133 d | 2026-03-27 |
| A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)NCT05095727Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment DiscontinuationNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: mRNA-3745 | Glycogen Storage Disease | 15 | 2026-11-30 | in 102 d | 2025-12-15 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy ParticipantsNCT05831111Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 1 | Active, not recruiting | Biological: mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195 | Epstein-Barr Virus Infection | 482 | 2026-10-13 | in 54 d | 2026-08-11 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and AdultsNCT05164094Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 1/2 | Active, not recruiting | Biological: mRNA-1189, Placebo | Epstein-Barr Virus Infection | 867 | 2026-10-05 | in 46 d | 2026-05-06 |
| A Retrospective Study to Characterize Participants With Propionic AcidemiaNCT05769621observationalNumber of Annualized Clinical Event Committee (CEC)-adjudicated Metabolic Decompensation Events (MDEs) | — | Recruiting | — | Propionic Acidemia | 60 | 2026-09-30 | in 41 d | 2026-02-05 |
| Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of AgeNCT05992935Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Randomized · Triple-masked · Prevention | Phase 1/2 | Active, not recruiting | Biological: mRNA-1403, mRNA-1405, Placebo | Norovirus Acute Gastroenteritis | 1,407 | 2026-09-22 | in 33 d | 2026-04-03 |
| A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsNCT06067230Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: mRNA-1345 | Respiratory Syncytial Virus | 1,153 | 2026-07-30 | — | 2025-08-08 |
| A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy ParticipantsNCT06655870Number of Participants with Treatment-emergent Adverse Events (TEAEs) Including Injection Site Reactions (ISRs), Adverse Events of Special Interests (AESIs), and Serious Adverse Events (SAEs)Randomized · Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: mRNA-0184 | Healthy Participants | 52 | 2026-06-23 | — | 2026-01-20 |
| A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and RecipientsNCT06133010Post-transplant: Time to the First Occurrence of a Clinically Significant Cytomegalovirus Infection (CS-CMVi) In Seropositive ParticipantsRandomized · Triple-masked · Prevention | Phase 2 | Withdrawnsponsor's stated reason: Trial was cancelled by Sponsor | Biological: mRNA-1647, Placebo | Cytomegalovirus Infection | 0 | 2027-02-14 | in 178 d | 2024-03-15 |
| A Dose-finding Study to Evaluate mRNA-3210 in Participants With PhenylketonuriaNCT06147856Number of Participants with Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: The Sponsor no longer intends to recruit to this study. | Drug: mRNA-3210 | Phenylketonuria | 0 | 2026-08-10 | — | 2024-10-22 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing FormulationsNCT07089706Subprotocol 1: Part A - Geometric Mean (GM) Value of Neutralizing Antibody (nAb) Against Vaccine-matched COVID-19 VariantsOpen-label · Prevention | Phase 4 | Completed | Biological: mRNA-1283.251 Variant-containing Formulation | COVID-19 | 832 | 2026-06-16actual | — | 2026-07-07 |
| mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)NCT05918250Number of Participants Experiencing Adverse EventsOpen-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: The Sponsor decided to discontinue development of mRNA-2736 for strategic business reasons. | Biological: mRNA-2736 | Relapsed or Refractory Multiple Myeloma | 0 | 2026-05-27 | — | 2023-08-18 |
| A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersNCT06143046Number of Maternal Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: mRNA-1345, Placebo | Respiratory Syncytial Virus | 360 | 2026-05-25actual | — | 2026-06-10 |
| A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of AgeNCT05575492Number of Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 1/2 | Completed | Biological: mRNA-1647 · Other: Placebo | Cytomegalovirus | 873 | 2026-05-12actual | — | 2026-06-04 |
| A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic AcidemiaNCT04899310Parts 1 and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Study Drug-related TEAEs, Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and TEAEs Leading to Treatment DiscontinuationRandomized · Triple-masked · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: As part of ongoing efforts to refine the MMA program strategy, we are reevaluating clinical study plans for mRNA-3705, in order to further optimize the development program. As part of this process, Moderna will be closing the mRNA-3705-P101 study. | Biological: mRNA-3705, Placebo | Methylmalonic Acidemia | 18 | 2026-04-01actual | — | 2026-05-06 |
| A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgeNCT07117487Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Open-label · Prevention | Phase 3 | Completed | Biological: mRNA-1345 | Respiratory Syncytial Virus | 507 | 2026-03-27actual | — | 2026-05-04 |
| A Study of Modified mRNA Vaccines in Healthy AdultsNCT05397223Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Randomized · Open-label · Prevention | Phase 1 | Completed | Biological: mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647 | SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus | 308 | 2026-02-27actual | — | 2026-03-12 |
| A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccineNCT04975893Primary Extension Phase: Geometric Mean Titers (GMTs) of Antigen-Specific Neutralizing Antibody (nAb) and Binding Antibody (bAb)Non-randomized · Open-label · Prevention | Phase 2 | Completed | Biological: mRNA-1647 · Other: mRNA-1647 | Cytomegalovirus Infection | 135 | 2026-01-19actual | — | 2026-02-02 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of AgeNCT05701800Number Participants with Solicited Local and Systemic Reactogenicity Adverse ReactionsRandomized · Triple-masked · Prevention | Phase 1 | Terminatedsponsor's stated reason: The clinical study was terminated prior to the start of Phase 2 following a business decision to discontinue further development of the vaccine. | Biological: mRNA-1468, Placebo, Shingrix | Herpes Zoster | 659 | 2025-12-31actual | — | 2026-08-05 |
| Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgeNCT06694389Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) AssayRandomized · Double-masked · Prevention | Phase 3 | Completed | Biological: mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine · Other: Placebo | COVID-19, Influenza | 2,457 | 2025-11-17actual | — | 2025-12-02 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsNCT05606965Parts A, B, and C: Number of Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Randomized · Open-label · Prevention | Phase 2 | Completed | Biological: mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine, mRNA-1345, mRNA-1045 | Influenza | 172 | 2025-11-13actual | — | 2025-11-24 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgeNCT05085366Seroconversion From a Negative to a Positive Result for Serum Immunoglobulin G (IgG) Against Antigens not Encoded by mRNA-1647Randomized · Quadruple-masked · Prevention | Phase 3 | Terminatedsponsor's stated reason: The Sponsor decided to terminate the study after it did not meet the primary efficacy endpoint at final analysis. The safety profile was consistent with prior studies, and no safety concerns were raised by the Data and Safety Monitoring Board. | Biological: mRNA-1647, Placebo | Cytomegalovirus Infection | 7,454 | 2025-11-04actual | — | 2025-12-15 |
| A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of AgeNCT05436834Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Non-randomized · Open-label · Prevention | Phase 3 | Completed | Biological: mRNA-1273.214, mRNA-1273.815 | SARS-CoV-2 | 1,807 | 2025-10-20actual | — | 2025-11-26 |
| A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of AgeNCT06864143Geometric Mean Titer (GMT) as Measured by Hemagglutination Inhibition (HAI) Assay for InfluenzaRandomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B | Influenza, SARS-CoV-2 | 1,320 | 2025-10-13actual | — | 2025-10-20 |
| A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)NCT06508320Geometric Mean Value of Antibodies at Day 29, as Measured by Hemagglutinin Inhibition (HAI) Assay for InfluenzaRandomized · Double-masked · Prevention | Phase 2 | Completed | Biological: mRNA-1083 | Influenza, SARS-CoV-2 | 932 | 2025-09-25actual | — | 2025-10-14 |
| A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeNCT06602024Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Triple-masked · Prevention | Phase 3 | Completed | Biological: mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra | Seasonal Influenza | 40,817 | 2025-08-21actual | — | 2025-09-10 |
| Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced MalignanciesNCT03739931Number of Participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: mRNA-2752, Durvalumab | Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma | 134 | 2025-08-01actual | — | 2025-08-15 |
| A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeNCT05127434Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 2/3 | Completed | Drug: Placebo, mRNA-1345 | Respiratory Syncytial Virus | 36,814 | 2025-07-28actual | — | 2025-08-19 |
| A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of AgeNCT05995275Number of Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) Through 7 Days After Each Investigational Medicinal Product (IMP)Randomized · Quadruple-masked · Prevention | Phase 1/2 | Completed | Biological: mRNA-1769 · Other: Placebo | Smallpox, Mpox | 351 | 2025-07-08actual | — | 2025-07-16 |
| A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial VirusNCT06097299results2026-08-18Part A (Cohorts 1 and 2): Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: mRNA-1345, Placebo | Respiratory Syncytial Virus | 349 | 2025-06-27actual | — | 2026-08-18 |
| Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy ParticipantsNCT06243770Number of Participants with Treatment-emergent Adverse Events (TEAEs)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: mRNA-0184 | Healthy Participants | 44 | 2025-06-12actual | — | 2025-08-01 |
| A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of AgeNCT05975099results2026-07-30Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 InjectionRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: mRNA-1975, mRNA-1982, Placebo | Lyme Disease | 807 | 2025-05-30actual | — | 2026-07-30 |
| A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital HerpesNCT06033261results2026-05-08Number of Participants With Solicited Local and Systemic ARsRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: mRNA-1608, BEXSERO | Genital Herpes | 303 | 2025-04-25actual | — | 2026-05-08 |
| A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19NCT05815498results2026-05-01Part 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 29Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: mRNA-1283.222, mRNA-1273.222, mRNA-1283.815, mRNA-1273.815 | COVID-19 | 13,553 | 2025-04-12actual | — | 2026-05-01 |
| A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of AgeNCT06634797results2026-02-04Number of Participants With Elevated Cardiac Troponin I (cTnI) at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2)Randomized · Triple-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: mRNA-1273.712, Placebo | Healthy Volunteers | 1,000 | 2025-01-20actual | — | 2026-02-04 |
| A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart FailureNCT05659264Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Randomized · Single-masked · Treatment | Phase 1 | Completed | Drug: mRNA-0184, Placebo | Chronic Heart Failure | 48 | 2024-12-17actual | — | 2025-03-17 |
| A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy AdultsNCT05827926results2025-12-23Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2 | SARS-CoV-2, Influenza | 1,758 | 2024-12-03actual | — | 2025-12-23 |
| Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in InfantsNCT05584202results2025-11-26Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First InjectionRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The trial was terminated because data from the dose finding part of the trial did not support further evaluation of effectiveness of mRNA-1273. There were no safety concerns. | Biological: mRNA-1273.214 · Other: Placebo | SARS-CoV-2 | 68 | 2024-11-15actual | — | 2025-11-26 |
| A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgeNCT05330975results2025-12-30Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 InjectionRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214 | Respiratory Syncytial Virus | 3,317 | 2024-11-08actual | — | 2025-12-30 |
| A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 VaccineNCT06113692observationalNumber of Participants With Myocarditis and/or Pericarditis within 30 Days After Moderna vaccination targeting SARS-CoV-2 | — | Completed | Biological: mRNA-1273 | Myocarditis, Pericarditis | 1,169 | 2024-08-31actual | — | 2025-08-01 |
| A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus AreasNCT04917861results2025-09-25Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Biological: mRNA-1893, Placebo | Zika Virus | 808 | 2024-07-26actual | — | 2025-09-25 |
| A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-SeropositiveNCT04528719Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: mRNA-1345 · Drug: Placebo | Respiratory Syncytial Virus | 651 | 2024-07-18actual | — | 2024-08-07 |
| A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy AdultsNCT05972174Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Triple-masked · Prevention | Phase 1/2 | Completed | Biological: mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only, mRNA-1018 for H7 Only, mRNA-1018 for H5 Only-CG | Influenza | 1,504 | 2024-07-16actual | — | 2025-07-16 |
| Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsNCT05827978results2025-07-10Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody Levels as Measured by Hemagglutination Inhibition (HAI)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Seasonal Influenza | 8,411 | 2024-06-24actual | — | 2025-07-10 |
| An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)NCT05765578observationalGeometric Mean Titer (GMT) of Serum Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Binding Antibody Titers Against Omicron BA.4/5 at Day 29 Between MMMM Group and PPPP Group | — | Completed | Biological: Moderna COVID-19 Vaccine, Moderna mRNA1273.222 Booster, Pfizer COVID-19 Vaccine, Moderna 2023 Updated COVID-19 vaccine (XBB.1.5), Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5) | COVID-19 | 1,713 | 2024-06-17actual | — | 2024-07-31 |
| A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19NCT04649151results2025-09-15Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2/3 | Completed | Biological: mRNA-1273, Placebo, mRNA-1273.222 | SARS-CoV-2 | 4,328 | 2024-06-14actual | — | 2025-09-15 |
| A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of AgeNCT06060457results2025-07-30Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 InjectionRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Placebo, mRNA-1345, Fluzone HD | Respiratory Syncytial Virus | 1,900 | 2024-06-07actual | — | 2025-07-30 |
| A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of AgeNCT06097273results2025-06-13Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) AssayRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine | SARS-CoV-2, Influenza | 8,061 | 2024-05-28actual | — | 2025-07-01 |
| A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated AdultsNCT06354998results2025-05-25Geometric Mean (GM) Value of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 15Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Investigational mRNA-1273.815, Licensed Spikevax Vaccine | SARS-CoV-2 | 217 | 2024-05-10actual | — | 2025-05-25 |
| A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of AgeNCT04796896results2025-06-13Parts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2/3 | Completed | Biological: mRNA-1273, Placebo, mRNA-1273.214 | SARS-CoV-2 | 11,942 | 2024-03-15actual | — | 2025-06-13 |
| Post-marketing Safety of Elasomeran/Davesomeran and AndusomeranNCT06130345observationalNumber of Participants With Adverse Events of Special Interest (AESI) | — | Completed | Biological: SPIKEVAX | SARS-CoV-2 | 15,196,685 | 2024-02-29actual | — | 2024-12-19 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years OldNCT05585632Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230 | SARS-CoV-2, Influenza, RSV | 392 | 2024-02-28actual | — | 2024-03-08 |
| A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and OlderNCT05566639results2025-01-16Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Randomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: mRNA-1010, Fluarix Quadrivalent | Seasonal Influenza | 22,502 | 2024-01-05actual | — | 2025-01-16 |
| Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19NCT05894590observationalNumber of Participants With Serious Events Associated With all-Cause Hospitalizations | — | Completed | — | SARS-CoV-2 | 13,680 | 2023-12-20actual | — | 2024-03-15 |
| Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy AdultsNCT05868382results2024-12-20Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: mRNA-1010, mRNA-1010.4, mRNA-1010.6 | Influenza | 270 | 2023-12-19actual | — | 2024-12-20 |
| A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy AdultsNCT05827068results2025-02-03Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3 | Seasonal Influenza | 698 | 2023-11-20actual | — | 2025-02-03 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) VariantsNCT04927065results2025-02-28Number of Participants With Solicited Local and Systemic ARsNon-randomized · Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Biological: mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, mRNA-1273.231 | SARS-CoV-2 | 5,161 | 2023-11-17actual | — | 2025-02-28 |
| A Study of the Effectiveness of Moderna COVID-19 VaccineNCT05933304observationalNumber of Participants With SARS-CoV-2 Infection | — | Completed | — | SARS-CoV-2, COVID-19 | 927,004 | 2023-11-17actual | — | 2025-05-28 |
| Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During PregnancyNCT06369272observationalNumber of MCMs | — | Completed | — | Maternal Outcomes, Infant Outcomes, Pregnancy | 1,192 | 2023-10-20actual | — | 2024-04-16 |
| Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) StudyNCT05572658observationalRate of Hospitalizations for Cardiopulmonary, Cardiovascular, Respiratory, Pneumonia/Influenza, Pneumonia and Complications, or RSV | — | Completed | Biological: mRNA-1345, Placebo | Respiratory Syncytial Virus | 10,994 | 2023-09-30actual | — | 2025-01-24 |
| Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome StudyNCT04958304observationalNumber of Participants Having Infants With Suspected Major and Minor Congenital Malformations | — | Terminatedsponsor's stated reason: Study has been terminated and replaced due to low enrollment. | — | SARS-CoV-2 | 20 | 2023-09-22actual | — | 2023-11-28 |
| A Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsNCT05415462results2024-09-24Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B StrainsRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: mRNA-1010, Fluarix Tetra | Seasonal Influenza | 6,102 | 2023-09-04actual | — | 2024-09-24 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647NCT05105048Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: mRNA-1647, Placebo | Cytomegalovirus Infection | 9 | 2023-08-10actual | — | 2023-09-11 |
| A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19NCT04813796Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Randomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: mRNA-1283, mRNA-1273, Placebo | SARS-CoV-2 | 104 | 2023-07-25actual | — | 2023-08-01 |
| A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19NCT05249829results2024-08-09Part 1: Geometric Mean Concentration (GMC) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Biological: mRNA-1273.529, mRNA-1273, mRNA-1273.214 | SARS-CoV-2 | 3,548 | 2023-06-23actual | — | 2024-08-09 |
| Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19NCT05894499observationalNumber of Participants With Hypersensitivity Reactions Including Shock and Anaphylaxis After Either Dose 1 and Dose 2 | — | Completed | — | SARS-CoV-2 | 13,309 | 2023-05-26actual | — | 2024-03-15 |
| Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 VaccineNCT05894525observationalNumber of Participants With Solicited Acute Adverse Events | — | Completed | — | SARS-CoV-2 | 8,844 | 2023-05-26actual | — | 2024-03-15 |
| A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult ParticipantsNCT04860297results2024-06-18Parts A and B: Number of SOT Participants With Unsolicited Adverse Events (AEs)Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: mRNA-1273 | SARS-CoV-2 | 234 | 2023-05-22actual | — | 2024-06-18 |
| Long-Term Follow-up Survey of COVID-19 Vaccine After VaccinationNCT04941144observationalPercentage of Participants with Serious Adverse Events (SAE) | — | Completed | Biological: COVID-19 Vaccine | Coronavirus Disease (COVID-19) | 8,538 | 2023-04-28actual | — | 2023-05-19 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine BoostersNCT05137236results2025-07-17Parts A and B: Number of Participants With Solicited Local and Solicited Systemic Reactogenicity Adverse Reactions (ARs)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: mRNA-1283, mRNA-1283.211, mRNA-1273, mRNA-1283.529 | SARS-CoV-2 | 540 | 2023-03-23actual | — | 2025-07-17 |
| Use of Wearable Digital Sensors After mRNA Vaccination in AdultsNCT05440318observationalChange From Pre-vaccination Baseline in Heart Rate up to 7 Days After Vaccination | — | Completed | Device: Wireless wearable digital devices | Healthy Participants | 62 | 2023-02-07actual | — | 2023-04-04 |
| Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy AdultsNCT04232280results2026-05-05Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: mRNA-1647 · Other: Placebo | Cytomegalovirus Infection | 315 | 2023-01-04actual | — | 2026-05-05 |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19NCT04470427results2024-03-21Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second DoseRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 3 | Completed | Biological: mRNA-1273, Placebo | SARS-CoV-2 | 30,415 | 2022-12-29actual | — | 2024-03-21 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years OldNCT05375838results2024-02-28Number of Participants With Solicited Local and Systemic Adverse Reaction (ARs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: mRNA-1073, mRNA-1010, mRNA-1273, Placebo | SARS-CoV-2, Influenza | 550 | 2022-12-29actual | — | 2024-02-28 |
| Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior ExposureNCT04144348Proportion of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: mRNA-1653, Placebo | Human Metapneumovirus and Human Parainfluenza Infection | 51 | 2022-12-20actual | — | 2023-02-03 |
| A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy AdultsNCT05333289results2024-02-01Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: mRNA-1030, mRNA-1020, mRNA-1010, Active Comparator | Seasonal Influenza | 572 | 2022-11-22actual | — | 2024-02-01 |
| A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy AdultsNCT04956575results2023-10-27Number of Participants With Solicited Local and Systemic ARsRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: mRNA-1010, Placebo, Active Comparator | Seasonal Influenza | 885 | 2022-09-27actual | — | 2023-10-27 |
| Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United StatesNCT04958954observationalNumber of Participants With Adverse Events of Special Interests (AESIs) | — | Completed | — | SARS-CoV-2 | 50,000,000 | 2022-08-31actual | — | 2023-07-17 |
| A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any KindNCT05367908observationalChange in Antibody Levels Since Receiving a COVID-19 Booster Vaccine at 0, 1, and 2 Months Post Enrollment | — | Completed | — | SARS-CoV-2 | 1,501 | 2022-08-14actual | — | 2022-10-13 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy AdultsNCT04916431Number of Participants with Adverse Events (AEs) and Serious AEsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: mRNA-6231 | Healthy Volunteers | 18 | 2022-08-02actual | — | 2022-08-10 |
| A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised AdultsNCT05366322observationalNumber of Participants with Medically Attended Breakthrough COVID-19 Diagnosis | — | Completed | — | SARS-CoV-2 | 124,879 | 2022-02-04actual | — | 2022-05-09 |
| Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and OlderNCT04405076results2022-12-30Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Randomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Biological: Biological: mRNA-1273, Placebo, mRNA-1273.351 | SARS-CoV-2 | 660 | 2021-10-28actual | — | 2022-12-30 |
| Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced MalignanciesNCT03323398results2024-07-31Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: This study was halted prematurely because the efficacy endpoints were not met for either treatment arm. | Biological: mRNA-2416, Durvalumab | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer | 79 | 2021-08-18actual | — | 2024-07-31 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy AdultsNCT03829384Frequency of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESI) and laboratory abnormalitiesRandomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: mRNA-1944 · Other: Placebo | Prevention of Chikungunya Virus Infection | 39 | 2021-06-07actual | — | 2021-07-07 |
| "The MaP Study": Mapping the Patient Journey in MMA and PANCT03484767observationalChange in plasma methylmalonic acid levels (MMA only) | — | Completed | — | Methylmalonic Acidemia, Propionic Acidemia | 97 | 2021-05-29actual | — | 2021-08-02 |
| Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative AdultsNCT04064905results2024-06-17Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reaction (ARs)-First VaccinationRandomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 1 | Completed | Biological: mRNA-1893 · Other: Placebo | Zika Virus | 120 | 2021-03-22actual | — | 2024-08-21 |
| Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy AdultsNCT03382405Frequency of solicited AEs (local and systemic reactogenicity events)Randomized · Double-masked · Prevention | Phase 1 | Completed | Biological: mRNA-1647, mRNA-1443 · Other: Placebo | Cytomegalovirus Infection | 181 | 2020-10-28actual | — | 2021-01-15 |
| Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic AcidemiaNCT03810690Incidence of treatment-emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Study was terminated before the start of dosing due to a business decision and not due to safety or efficacy reasons. | Biological: mRNA-3704 | Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors | 0 | 2020-08-18actual | — | 2020-11-13 |
| Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult SubjectsNCT03014089results2024-06-17Part A: Number of Participants With Solicited Adverse Events- Vaccination 1Randomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 1 | Completed | Biological: mRNA-1325 · Other: Placebo | Zika Virus | 90 | 2019-07-31actual | — | 2024-08-21 |
| Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy AdultsNCT03392389Frequency of solicited AEs (local and systemic reactogenicity events)Randomized · Double-masked · Prevention | Phase 1 | Completed | Biological: mRNA-1653 · Other: Placebo | Human Metapneumovirus and Human Parainfluenza Infection | 124 | 2019-07-29actual | — | 2020-02-06 |
| Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy ParticipantsNCT03325075results2024-06-10Part A: Number of Participants With Any Solicited Adverse Events (AEs) (Local and Systemic Reactogenicity Events)Randomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 1 | Completed | Biological: VAL-181388 · Other: Placebo | Chikungunya Virus | 60 | 2019-03-19actual | — | 2024-06-10 |
| Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult SubjectsNCT03076385Types, frequency, and severity of serious adverse events (SAE), adverse events of special interest (AESI), and adverse events considered related to study drugRandomized · Double-masked · Prevention | Phase 1 | Completed | Biological: VAL-506440 · Other: Placebo | Influenza | 201 | Oct 2018actual | — | 2022-04-22 |
| Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult SubjectsNCT03345043Frequency of solicited AEs (local and systemic reactogenicity events)Randomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: VAL-339851 · Other: Placebo | Influenza | 156 | 2018-08-13actual | — | 2021-01-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19